Introduction
Idazoxan and many other imidazoline and guanidinium derivatives with high binding anity to a 2 -adrenoceptors bind also to non-adrenoceptor binding sites in renal tissues in a variety of species (Coupry et al., 1987; Vigne et al., 1989; Lachaud-Pettiti et al., 1991; Wikberg et al., 1992; Evans & Haynes, 1994) . These non-adrenergic imidazoline binding sites or I-imidazoline receptors have been subclassi®ed into two major groups Michel & Ernsberger, 1992; Parini et al., 1996) . The binding sites identi®ed by [ 3 H]para-aminoclonidine, which have high anity for imidazoline and oxazoline derivatives such as rilmenidine and moxonidine, are designated as I 1 -imidazoline receptors, and those identi®ed by [ 3 H]idazoxan, which have high anity for guanidinium derivatives such as guanabenz, as l 2 -imidazoline receptors. It has been hypothesized that a subpopulation of l 2 -imidazoline receptors represents a previously unknown ligand binding domain on monoamine oxidase (MAO) which is distinct from MAO's catalytic domain (Raddatz et al., 1995) . The imidazoline binding site present on pancreatic islet cells and involved in the control of insulin secretion represents an atypical I-imidazoline receptor (Chan et al., 1994; Olmos et al., 1994) ; this site has been termed an I 3 -imidazoline receptor (Eglen et al., 1998) .
The imidazole derivative atipamezole was ®rst described as a potent, speci®c and selective a 2 -adrenoceptor antagonist (Scheinin et al., 1988; Virtanen et al., 1989) . However, in some tissues [ 3 H]atipamezole identi®es an additional population of binding sites, distinct from both classic a 2 -adrenoceptors and I 1 -and I 2 -imidazoline receptors identi®ed with [ 3 H]paraaminoclonidine or [ 3 H]idazoxan (SjoÈ holm et al., 1992; . The I 1 -imidazoline receptors in the central nervous system and in the kidney may have a role in mediating the hypotensive actions of imidazoline and oxazoline drugs, such as clonidine, rilmenidine and moxonidine (Ernsberger et al., 1993) . Stimulation of renal I 1 -imidazoline receptors with moxonidine increases solute excretion (Allan et al., 1993) . The role of the I 2 -imidazoline receptor in kidney function is more unclear, but it has been suggested that idazoxan inhibits Na + /H + exchange in renal proximal tubule cells through an interaction with I 2 -imidazoline receptors (Bidet et al., 1990) . The purpose of the present study was to characterize [ 3 H]atipamezole binding sites in rat kidney and to determine whether they are pharmacologically identical with the previously described imidazoline receptors identi®ed with [ 3 H]para-aminoclonidine and [
3 H]idazoxan (Ernsberger et al., 1990; MacKinnon et al., 1993 (SjoÈ holm et al., 1996) .
Methods

Tissue preparation
For receptor autoradiography, adult male Sprague-Dawley rats were killed by decapitation and their kidneys were rapidly removed and decapsulated. The kidneys were frozen by immersion in cold isopentane in a dry ice bath. Frozen 14 mm transverse sections were cut and thaw-mounted onto gelatinized slides and stored at 7708C until used for autoradiography. Additional sections were stained with hematoxylin and eosin for histological examination. For membrane binding assays, kidneys were rapidly removed from decapitated rats (Sprague-Dawley of either sex) and decapsulated followed by dissection. Two regions were prepared from separate kidneys: the renal cortex and the outer stripe of the outer medulla, and the inner medulla. The tissues were homogenized using an Ultra-Turrax (2615 s) in 20 volumes of ice-cold 50 mM Tris-HCl, 0.8 mM EDTA, pH 7.5 at 48C. The homogenates were ®rst centrifuged at 10006g for 5 min at 48C to remove large particles, and the supernatants were centrifuged at 45,0006g for 25 min at 48C. The pellets were suspended in 20 volumes of the same buer and the homogenization and centrifugation were repeated. The resulting pellets were washed with incubation buer (50 mM K + -phosphate buer, pH 7.4 at 258C) and recentrifuged at 45,0006g for 25 min at 48C. The ®nal membrane pellets were diluted with incubation buer ten times the original wet tissue weight and stored at 7708C.
Protein concentrations were determined by the method of Bradford (1976) with bovine serum albumin as the reference standard.
Receptor autoradiography
At least three kidneys from three dierent animals were used in each experiment. (Kriz & Bankir, 1988) and measured: cortex, outer stripe of outer medulla, inner stripe of outer medulla, and inner medulla. were performed in the presence of 10 mM RX821002 to preclude binding to a 2 -adrenoceptors. The incubations were terminated by dilution with 2 ml of ice-cold TM-buer (50 mM Tris, 10 mM MgCl 2 , pH 7.4 at 48C) and rapid ®ltration through presoaked ®breglass ®lters (Whatman GF/ B) using a Brandel (Gaithersburg, MD, U.S.A.) cell harvester. The ®lters were washed twice with 5 ml of the same buer, and radioactivity remaining on the ®lters was quanti®ed by liquid scintillation counting. Non-speci®c binding was de®ned with parallel incubations containing 1 mM unlabelled atipamezole or 5 mM detomidine for 
Membrane binding assay
Monoamine oxidase A and B assay
Monoamine oxidase A and B activity was assayed radiochemically as described by Keller et al. (1987) , with minor modi®cations. 100 ml of rat renal membranes (about 0.1 and 0.4 mg of protein in MAO-A and -B assays, respectively) were preincubated with 0 ± 10 mM unlabelled atipamezole in reaction buer for 1 min at 378C before substrate addition. The reaction was carried out in 0.1 M potassium phosphate buer (pH 7.4, total volume 0.5 ml) using 200 mM 
Data analysis
The Prism regression analysis program (GraphPad Software, San Diego, CA, U.S.A.) was used to calculate the best-®tting values for the parameters of saturation isotherms (K D and B max ) and competition curves (IC 50 ) under an assumption of no co-operativity between sites (Hill slope & 1). The saturation data were analysed using one-site models, which failed to account for another population of binding sites for [ 3 Table 2 . In renal cortex, [ 3 H]atipamezole binding was displaced by detomidine with an IC 50 of 0.18 mM. MPV-624 had intermediate anity and para-aminoclonidine and idazoxan had low anity. [ 3 H]Atipamezole binding in the outer stripe of the outer medulla appeared to dier from renal cortex: Detomidine and MPV-624 were less potent than in cortex, and idazoxan and para-aminoclonidine were unable to displace the radioligand (Figure 3) . The putative endogenous imidazoline receptor ligand, agmatine (Li et al., 1994) Competition studies A series of imidazoles, imidazolines and guanidinium derivatives was tested for their ability to inhibit non-adrenergic binding of [ was potently displaced by a number of a 2 -adrenergic imidazoles, e.g. detomidine and MPV-295 (Table 4 ). In addition, the cytochrome P450 inhibitor ketoconazole had moderate anity for these binding sites, while the histamine H 2 -antagonist cimetidine had low anity. Furthermore, imidazoli(di)nes such as para-aminoclonidine and phentolamine were moderately, and idazoxan was poorly eective in inhibiting the binding of [ In saturation studies, the binding of [ 3 H]RX821002 to membranes from rat renal cortex and outer stripe of the outer medulla was saturable (B max =120+9 fmol per mg protein) and of high anity (K D =0.96+0.06 nM; n=6). Analysis of the competition curves for oxymetazoline, chlorpromazine and prazosin revealed that all binding results with these compounds were signi®cantly better ®t to a two-site model of binding than to a one-site model (Figure 4) . The calculated IC 50 -values for the two sites were 52 nM and 0.8 mM for oxymetazoline, 57 nM and 3.8 mM for chlorpromazine and 35 nM and 2.1 mM for prazosin. In each case, the high anity component of binding represented 50 ± 60% of the speci®cally bound ligand. In membranes of inner medulla, speci®c 
Monoamine oxidase activity
The basal monoamine oxidase activity in rat renal membranes, in the assay conditions described in the Methods section, was 107+3 nmol mg protein 71 h 71 (n=4) for MAO-A and 12.1+0.6 nmol mg protein 71 h 71 (n=3) for MAO-B. Atipamezole (from 1 nM ± 10 mM) had no eect on the MAO-A and MAO-B activities (104+0.1 and 11.7+0.3 nmol mg protein 71 h 71 at 10 mM).
Discussion
We have demonstrated that [ 3 H]atipamezole binding to rat kidney recognizes a large population of non-adrenoceptor sites. The dissociation of [ 3 H]atipamezole from all three a 2 -adrenoceptor subtypes is rapid (Halme et al., 1995) (Stephenson & Summers, 1985; Meister et al., 1994) .
Non-adrenergic imidazoline binding sites in various tissues are subclassi®ed as I 1 -, I 2 -and I 3 -sites based on their ability to recognize various imidazoline or guanidinium ligands (Michel & Ernsberger, 1992; Eglen et al., 1998 The proportion of the low anity component (IC 50(2) ) ranged from 54 ± 72%. The membranes were incubated with 0.6 nM [ 3 H]RX821002 in membranes of rat renal cortex and the outer stripe of the outer medulla: results for the relatively subtype-selective ligands oxymetazoline, chlorpromazine, and prazosin. Data points represent means +s.e.mean (shown where greater than the symbols) of ®ve experiments. The data for all three compounds were best described by a two-site model. See text for IC 50 -values. central nervous system and in rat kidney and is recognized by many imidazole compounds (Ernsberger et al., 1987 ]para-aminoclonidine site described above, I 2 -sites have high anity also for guanidinium derivatives. The I 2 -imidazoline receptors can be further subclassi®ed into I 2A -and I 2B -sites based upon dierential recognition of the guanidinium compound amiloride (Michel & Ernsberger, 1992; Parini et al., 1996) . The I 3 -imidazoline receptor is involved in control of insulin secretion. This I 3 -binding site is recognized also by [ 3 H]RX821002 (Chan et al., 1994) . Indeed, the a 2 -adrenergic ligand RX821002 (2-methoxy-idazoxan) is an imidazoline compound which functions as an insulin secretagogue in isolated rat islets (Chan et al., 1994) and isolated perfused rat pancreas (Berdeu et al., 1994) ; it does not signi®cantly interact with I 1 -or I 2 -imidazoline receptors (Langin et al., 1990) but has relatively high anity to I 3 -imidazoline receptors (K D minimum estimate 124 nM; Chan et al., 1994) . Idazoxan is not functionally active in the pancreatic b-cells .
In A series of competition experiments was performed with membranes from rat renal cortex and outer stripe of outer medulla to further determine the pharmacological speci®city of non-adrenergic [
